Polysaccharide-K

Developed for: HER2 positive breast carcinoma
Investigated by: National Cancer Institute (NCI) · National Center for Complementary and Integrative Health (NCCIH) · University of Washington

today NCT01922921 · Ph 1/2

20142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT01922921	Feb 2014 → Oct 2019	HER2 positive breast carcinoma	University of Washington	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Polysaccharide-K	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01922921 ↗
Route	Oral	“polysaccharide-K PO BID for 4 months” NCT01922921 ↗